Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting resources
  3. ESMO 2018 Congress

Satellite Symposium BOEHRINGER INGELHEIM - Treating lung cancer in a rapidly evolving landscape

Sequencing in EGFR-mutated NSCLC: Does order matter?

Date

21 Oct 2018

Session

Satellite Symposium BOEHRINGER INGELHEIM - Treating lung cancer in a rapidly evolving landscape

Topics

Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Maximilian Hochmair

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

At ESMO 2018, Maximilian Hochmair discussed how the availability of third-generation TKIs provides additional treatment options for patients with EGFR mutation positive NSCLC, but raises questions about the optimal sequence of EGFR TKIs. In this highlights video, he discusses resistance mechanisms to EGFR TKIs and shares data from the recently published GioTag study.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.